Sunday, May 8, 2022 3:45 PM – 5:45 PM ET Room A105–106
CD4+ T Cells in Cancer
Chairs
- Stephen Schoenberger, La Jolla Inst. for Immunology
- Steven Ziegler, Benaroya Res. Inst.
Speakers
- Spencer E. Brightman, La Jolla Inst. for Immunology, TCR-engineered neoantigen-specific CD4+ T cells mediate immunotherapy of a class II-negative murine squamous cell carcinoma
- Katelyn T. Byrne, Perelman Sch. of Med., Univ. of Pennsylvania, CD4+ T cells mediate non-canonical rejection of major histocompatibility class-I deficient pancreatic tumors independently of CD8+ T cells
- Dan Chen, Salk Inst. for Biological Studies, Dissecting anti-tumor immunity in glioblastoma
- Ying Zheng, Johns Hopkins Univ. Sch. of Med., Target the activin receptor 1c on CD4+ T cells to achieve anti-tumor therapeutic effects
- Hsin Yu Liu, La Jolla Inst. for Immunology, Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy
- Kazushige Obata-Ninomiya, Benaroya Res. Inst., Virginia Mason, Thymic stromal lymphopoietin (TSLP) receptor signaling controls a tumorigenic Treg to promote colorectal cancer
- Kai Yang, Indiana Univ. Sch. of Med., The glutathione peroxidase Gpx4 prevents Treg lipid peroxidation and ferroptosis to facilitate tumor immunoevasion